75 Participants Needed

Brain Activity Study for Cognitive Impairment in Parkinson's Disease

SB
DS
SK
HQ
IL
Overseen ByIsabel Long, BS
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Vanderbilt University Medical Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

Is the treatment generally safe for humans?

The research articles provided do not contain specific safety data for the treatment involving corticosteroids or other names for cognitive impairment in Parkinson's disease.12345

How does this treatment for cognitive impairment in Parkinson's disease differ from other treatments?

This treatment is unique because it focuses on brain activity related to cognitive impairment, which may involve non-dopaminergic systems that are not addressed by standard dopamine replacement therapies like levodopa. Unlike traditional treatments that primarily target motor symptoms, this approach may offer insights into cognitive aspects of Parkinson's disease.34678

What is the purpose of this trial?

The goal of this study is to learn more about the brain activity underlying Parkinson's disease cognitive impairment. The investigators will utilize neural recordings from corticostriatal structures performed during deep brain stimulation surgery to measure neural activity underlying nonmotor symptoms of Parkinson's disease.

Research Team

SB

Sarah Bick, MD

Principal Investigator

Vanderbilt University Medical Center

Eligibility Criteria

This trial is for English-speaking Parkinson's disease patients over 40, who are scheduled for deep brain stimulation surgery at Vanderbilt University Medical Center. Participants must be able to undergo intraoperative testing and have a clinical electrode trajectory that contacts the caudate.

Inclusion Criteria

The planned electrode path will touch the caudate.
I am 40 years old or older.
I am scheduled for deep brain stimulation surgery at Vanderbilt under local anesthesia.
See 3 more

Exclusion Criteria

I am unable to follow instructions or directions during surgery.
I am under 40 years old.
I have a movement disorder that is not Parkinson's disease.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Deep Brain Stimulation Surgery

Neural recordings from corticostriatal structures are performed during deep brain stimulation surgery to measure neural activity underlying nonmotor symptoms of Parkinson's disease

3-4 hours

Follow-up

Participants are monitored for safety and effectiveness after the surgery

4 weeks

Treatment Details

Interventions

  • Corticosteroids
Trial Overview The study aims to understand cognitive impairment in Parkinson's by recording brain activity from corticostriatal structures during deep brain stimulation surgery. It will measure neural activity associated with nonmotor symptoms of the disease.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Neural recordings and stimulationExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Vanderbilt University Medical Center

Lead Sponsor

Trials
922
Recruited
939,000+

Findings from Research

Dopamine replacement medications can have mixed effects on cognitive abilities in Parkinson's disease patients, improving some skills while potentially worsening others, depending on disease severity.
Neuroimaging studies are helping to uncover the brain changes associated with cognitive decline in Parkinson's disease, particularly as patients transition from mild cognitive impairment to dementia.
The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging.Ray, NJ., Strafella, AP.[2022]
In a study of 124 non-demented Parkinson's disease patients, the type and side of initial motor symptoms did not predict the risk of later cognitive impairment, indicating that these factors may not be significant indicators of cognitive decline.
Patients with right-sided onset tremor exhibited the lowest depressive symptom scores, suggesting that this specific presentation may be associated with a reduced risk of depression compared to other motor symptom types.
Motor symptoms at onset of Parkinson disease and risk for cognitive impairment and depression.Dewey, RB., Taneja, A., McClintock, SM., et al.[2021]
In a study of 77 patients with Parkinson's disease over 4 years, only 22% showed a significant change (4 points or more) in cognitive function as measured by the Mini-Mental State Examination (MMSE) during a 2-year period.
Patients taking dopamine agonists were more likely to experience changes in their MMSE performance, suggesting that these medications may influence cognitive outcomes in Parkinson's disease.
Change in cognitive function in idiopathic Parkinson disease.Bayles, KA., Tomoeda, CK., Wood, JA., et al.[2019]

References

The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging. [2022]
Motor symptoms at onset of Parkinson disease and risk for cognitive impairment and depression. [2021]
Change in cognitive function in idiopathic Parkinson disease. [2019]
Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias. [2018]
Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. [2023]
6.Russia (Federation)pubmed.ncbi.nlm.nih.gov
[Dynamics of cognitive impairments during L-dopa therapy in Parkinson's disease]. [2021]
Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions? [2019]
Levodopa and executive performance in Parkinson's disease: a randomized study. [2013]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security